Dengue Vaccine Booster in Healthy Adolescents and Adults in Latin America: Evaluation 4–5 Years After a Primary 3-Dose Schedule

Background: The tetravalent dengue vaccine (CYD-TDV, Dengvaxia, Sanofi Pasteur) demonstrated efficacy in 2 previous phase III trials conducted in endemic countries. Neutralizing antibodies (NAbs) elicited by 3 doses of this vaccine have been associated with efficacy. Long-term follow-up data has shown that NAb immune responses tend to wane over time, after the third dose. This study compared the immune response elicited by a booster (4th) dose of CYD-TDV with the immune responses from the same participants obtained post-dose 3 of the primary series administered 4–5 years earlier. Methods: This multicenter, observer-blind, randomized, placebo-controlled, phase II noninferiority trial was conducted in healthy adolescents and adults in dengue endemic countries of Latin America (Colombia, Honduras, Brazil, Mexico and Puerto Rico). All participants had been immunized with 3 doses of CYD-TDV in phase II studies conducted 4–5 years earlier. NAb levels against each dengue virus serotype 28 days postbooster or placebo injection were reported. Results: A total of 187 participants received CYD-TDV and 64 received placebo. Prospectively defined noninferiority criteria for dengue NAbs after the booster dose compared with postdose 3 were met for all 4 serotypes. Prospectively defined superiority criteria were met for 3 of the 4 serotypes. Conclusions: Antidengue NAb levels can be boosted to levels at least as high as, or higher than those observed after completion of the primary 3-dose series, with an additional dose of CYD-TDV 4–5 years after the standard 3-dose vaccination schedule.

[1]  T. Westling,et al.  Effect of Dengue Serostatus on Dengue Vaccine Safety and Efficacy , 2018, The New England journal of medicine.

[2]  Lindsay N. Carpp,et al.  Neutralizing Antibody Correlates Analysis of Tetravalent Dengue Vaccine Efficacy Trials in Asia and Latin America , 2018, The Journal of infectious diseases.

[3]  Dengue vaccine: WHO position paper, September 2018 - Recommendations. , 2018, Vaccine.

[4]  B. Guy,et al.  Integrated immunogenicity analysis of a tetravalent dengue vaccine up to 4 y after vaccination , 2017, Human vaccines & immunotherapeutics.

[5]  H. Margolis,et al.  Evidence-based risk assessment and communication: a new global dengue-risk map for travellers and clinicians. , 2016, Journal of travel medicine.

[6]  G. Carrasquilla,et al.  Efficacy of a tetravalent dengue vaccine in children in Latin America. , 2015, The New England journal of medicine.

[7]  P. Pitisuttithum,et al.  Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial , 2014, The Lancet.

[8]  R. Dietze,et al.  Immunogenicity and Safety of a Recombinant Tetravalent Dengue Vaccine in Children and Adolescents Ages 9–16 Years in Brazil , 2013, The American journal of tropical medicine and hygiene.

[9]  M. Boaz,et al.  Safety and Immunogenicity of a Recombinant Tetravalent Dengue Vaccine in 9–16 Year Olds: A Randomized, Controlled, Phase II Trial in Latin America , 2013, The Pediatric infectious disease journal.

[10]  T. Timiryasova,et al.  Optimization and Validation of a Plaque Reduction Neutralization Test for the Detection of Neutralizing Antibodies to Four Serotypes of Dengue Virus Used in Support of Dengue Vaccine Development , 2013, The American journal of tropical medicine and hygiene.

[11]  P. Gething,et al.  Refining the Global Spatial Limits of Dengue Virus Transmission by Evidence-Based Consensus , 2012, PLoS neglected tropical diseases.